Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry

被引:105
作者
Lachâtre, F
Marquet, P
Ragot, S
Gaulier, JM
Cardot, P
Dupuy, JL
机构
[1] Univ Hosp, Dept Pharmacol & Toxicol, Limoges, France
[2] Univ Limoges, Fac Pharm, Analyt Chem Lab, Limoges, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2000年 / 738卷 / 02期
关键词
daunorubicin; doxorubicin; epirubicin; idarubicin; anthracyclines;
D O I
10.1016/S0378-4347(99)00529-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and very specific method, using liquid chromatography-electrospray mass spectrometry (LC-ES-MS), was developed for the determination of epirubicin, doxorubicin, daunorubicin, idarubicin and the respective active metabolites of the last three, namely doxorubicinol, daunorubicinol and idarubicinol in human serum, using aclarubicin as internal standard. Once thawed, 0.5-ml serum samples underwent an automated solid-phase extraction, using C-18 Bond Elut cartridges (Varian) and a Zymark Rapid-Trace robot. After elution of the compounds with chloroform-2-propanol (4:1, v/v) and evaporation, the residue was reconstituted with a mixture of 5 mM ammonium formate buffer (pH 4.5)-acetonitrile (60:40, v/v). The chromatographic separation was performed using a Symmetry C-18, 3.5 mu m (150x1 mm I.D.) reversed-phase column, and a mixture of 5 mM ammonium formate buffer (pH 3)-acetonitrile (70:30, v/v) as mobile phase, delivered at 50 mu l/min. The compounds were detected in the selected ion monitoring mode using, as quantitation ions, m/z 291 for idarubicin and idarubicinol, m/z 321 for daunorubicin and daunorubicinol, m/z 361 for epirubicin and doxorubicin, m/z 363 for doxorubicinol and m/z 812 for aclarubicin (I.S.). Extraction recovery was between 71 and 105% depending on compounds and concentration. The limit of detection was 0.5 ng/ml for daunorubicin and idarubicinol, 1 ng/ml for doxorubicin, epirubicin and idarubicin, 2 ng/ml for daunorubicinol and 2.5 ng/ml for doxorubicinol. The limit of quantitation (LOQ) was 2.5 ng/ml for doxorubicin, epirubicin and daunorubicinol, and 5 ng/ml for daunorubicin, idarubicin, doxorubicinol and idarubicinol. Linearity was verified from these LOQs up to 2000 ng/ml for the parent drugs (r greater than or equal to 0.992) and 200 ng/ml for the active metabolites (r greater than or equal to 0.985). Above LOQ, the within-day and between-day precision relative standard deviation values were all less than 15%. This assay was applied successfully to the analysis of human serum samples collected in patients administered doxorubicin or daunorubicin intravenously. This method is rapid, reliable, allows an easy sample preparation owing to the automated extraction and a high selectivity owing to MS detection. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 23 条
[1]  
[Anonymous], 1991, Therapeutic drugs
[2]   Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy [J].
Barker, IK ;
Crawford, SM ;
Fell, AF .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 681 (02) :323-329
[3]   HPLC DETERMINATION OF DOXORUBICIN, DOXORUBICINOL AND 4 AGLYCONE METABOLITES IN PLASMA OF AIDS PATIENTS [J].
BEIJNEN, JH ;
MEENHORST, PL ;
VANGIJN, R ;
FROMME, M ;
ROSING, H ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (10-12) :995-1002
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC BIOANALYSIS OF ANTHRACYCLINE CYTOSTATIC DRUGS [J].
BEIJNEN, JH ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1988, 6 (6-8) :677-685
[5]   Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties? [J].
Bielack, SS ;
Erttmann, R ;
KempfBielack, B ;
Winkler, K .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (10) :1652-1660
[6]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF IDARUBICIN AND FLUORESCENT METABOLITES IN BIOLOGICAL-FLUIDS [J].
CAMAGGI, CM ;
CARISI, P ;
STROCCHI, E ;
PANNUTI, F .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (04) :303-306
[7]   DETERMINATION OF ADRIAMYCIN, ADRIAMYCINOL AND THEIR 7-DEOXYAGLYCONES IN HUMAN-SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CUMMINGS, J ;
STUART, JFB ;
CALMAN, KC .
JOURNAL OF CHROMATOGRAPHY, 1984, 311 (01) :125-133
[8]   Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography [J].
de Bruijn, P ;
Verweij, J ;
Loos, WJ ;
Kolker, HJ ;
Planting, AST ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
ANALYTICAL BIOCHEMISTRY, 1999, 266 (02) :216-221
[9]   RAPID QUANTITATIVE-DETERMINATION OF EPIRUBICIN AND ITS METABOLITES IN PLASMA USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE DETECTION [J].
DINE, T ;
BRUNET, C ;
LUYCKX, M ;
CAZIN, M ;
GOSSELIN, P ;
CAZIN, JL .
BIOMEDICAL CHROMATOGRAPHY, 1990, 4 (01) :20-23
[10]   REVERSED-PHASE LIQUID-CHROMATOGRAPHIC DETERMINATION OF IDARUBICIN AND ITS 13-HYDROXY METABOLITE IN HUMAN-PLASMA [J].
EKSBORG, S ;
NILSSON, B .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 488 (02) :427-434